The research, published in Clinical Pharmacology: Advances and Applications, examined the effectiveness of the turmeric branded ingredient, TurmXTRA on knee pain after exercise.
The 90-day, randomized, double-blind, placebo-controlled, clinical trial was conducted in 96 healthy adults who experienced chronic knee pain following physical exertion resulting in significant improvement in terms of joint comfort, mobility, and performance post physical exertion. The subjects were given 250 mg of TurmXTRA, administered once daily.
The subjects reported improvement in efficacy variables as early as day 45, measurement of which was done on various test parameters that evaluated various aspects of mobility of joints and perception of pain, including a Visual Analogue 10 cm Scale following an 80 meter fast-paced walk.
The authors concluded that a three-month supplementation with 250 mg of TurmXTRA once daily, improved joint comfort and improved joint performance and mobility in healthy subjects with chronic knee pain.
“This study is pivotal since it showcases the benefits of a small dose of TurmXTRA, that in healthy subjects and as more people become active, a supplement that helps preserve knee structure and function we feel will be highly sought after,” said Anand Godbole, Inventia Assistant Vice -president of marketing & strategy.
The whole package
The study is the final installation of a complete clinical package which evolved from a preclinical study, which established bioequivalence of a 250 mg dose of TurmXTRA to 1575mg standard turmeric extract with 95% curcuminoids.
Godbole said the design of this clinical package is what stands out the most and is a significant feature of this research.
“Since the entire research has been done on a specific dose i.e. 250mg of TurmXTRA, whereas in normal parlance it has been observed that pharmacokinetics and clinical efficacy studies are conducted and non-related doses. Additionally, a very significant part of our study is that it was conducted in healthy subjects and the improvements are visible in healthy subjects, conventionally even though these products are intended for use in healthy populations as part of preventive supplementation most clinical substantiation is done in diseased populations. Therefore substantiation of the improvement in joint comfort for healthy people from a small 250mg dose translates to the most outstanding result in this study.”
What the research means
Godbole told NutraIngredients-USA that this research substantiates the low dose rationale of TurmXTRA.
“Therefore it opens up TurmXTRA as a viable option for reducing the dose of turmeric extract in supplements across therapeutic segments. Thereby tying in with our organizational base philosophy of wanting to provide benefits to our customers (brands) through innovative claims and product formats, and also allowing them to pass on the benefits to their customers--the end consumers.”
Source: Clinical Pharmacology: Advances and Applications
“A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain”
Authors: S. Thanawala et al.